RBC Capital lowered the firm’s price target on Chemed (CHE) to $572 from $589 and keeps an Outperform rating on the shares. The company reported solid Q3 results and reaffirmed full-year guidance, the analyst tells investors in a research note. While adjusted EBITDA in both VITAS and Roto-Rooter was slightly below Street consensus, the print was in line with the management’s expectations and serves as reaffirmation of its confidence in navigating challenges, RBC added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHE:
- Chemed Reports Mixed Q3 2025 Earnings Performance
- Chemed’s Earnings Call: Growth Amid Challenges
- Chemed reiterates FY25 EPS guidance of $22.00-$22,30, consensus $22.15
- Chemed reports Q3 adjusted EPS $5.27, consensus $5.36
- These 3 “Strong Buy” Value Stocks Have over 30% Upside, According to Analysts – 10/28/2025